Postoperative Analgesia
Conditions
Interventions
Group T1:Loading dose: Tegiletidine fumarate 1 mg was slowly administered via intravenous pump infusion 30 minutes before the end of surgery. PCIA regimen: Telitacicept fumarate 2.5 mg+ tropisetron 10
Group T2:Loading dose: Tegiletidine fumarate 1 mg was slowly administered via intravenous pump infusion 30 minutes before the end of surgery. PCIA regimen: Telitacicept fumarate 3 mg+ tropisetron 10 m
Group S:Loading dose: Sufentanil 3 µg was slowly administered via intravenous pump infusion 30 minutes before the end of surgery. PCIA regimen: Sufentanil 100 µg + tropisetron 10 mg + normal saline to
Sponsors
Affiliated Cancer Hospital of Guizhou Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18–65 years old; 2. Patients with gynecological malignancies scheduled for laparoscopic surgery; 3. American Society of Anesthesiologists (ASA) physical status classification ?–?; 4.Body mass index (BMI): 18.5 kg/m^2 < BMI < 30 kg/m^2; 5.Having a clear understanding of the study, voluntarily participating in the research, and providing written informed consent personally.
Exclusion criteria
Exclusion criteria: 1.Severe cardiovascular and cerebrovascular diseases: New York Heart Association (NYHA) functional classification >= ? or left ventricular ejection fraction (LVEF) = 160/100 mmHg; 3. A history of acute coronary syndrome or stroke within the previous 6 months; 4. Complicated by respiratory system diseases: patients with abnormal pulse oxygen saturation (SpO2) 7.5%; 8. Abnormal hepatic and renal function: Child-Pugh liver function score > 7, estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m^2; 9. A history of allergic diseases or hypersensitivity to the study drugs; 10. Pregnancy, lactation, or planned pregnancy in the near future; 11.Participation in other clinical trials of investigational drugs as a subject within the previous 3 months; 12.A history of alcoholism or substance abuse; 13.Presence of communication disorders, cognitive dysfunction, or mental illnesses, resulting in inability to cooperate with pain assessment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Numeric Rating Scale Score;Total number of effective PCA presses within 48 hours postoperatively;Utilization rate and total consumption of rescue analgesics; | — |
Secondary
| Measure | Time frame |
|---|---|
| Respiratory rate;Bruggrmann Comfort Scale (BCS);Adverse reactions;I-FEED score;Patient satisfaction score; | — |
Countries
China
Contacts
Public ContactLin Xiaofen
Affiliated Cancer Hospital of Guizhou Medical University
Outcome results
None listed